Health care stocks were mixed pre-bell Monday as the Health Care Select Sector SPDR Fund (XLV) was up 0.2% and the iShares Biotechnology ETF (IBB) declined by 0.4% recently.
Moderna (MRNA) shares fell by over 17% after the company said it now expects 2025 revenue to be between $1.5 billion and $2.5 billion, down from the previous range of $2.5 billion to $3.5 billion.
Intra-Cellular Therapies (ITCI) shares rallied by over 34% amid a deal for Johnson & Johnson (JNJ) to acquire the company for $132 per Intra-Cellular Therapies share in cash, for a total equity value of about $14.6 billion.
Option Care Health (OPCH) shares rose by over 14% after the company said it expects to report Q4 adjusted earnings per diluted share of $0.42 to $0.45 and up to a 20% increase in net revenue to between $1.34 billion and $1.35 billion.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。